Alberta-Wide Funding Opportunity in Diabetes Research – LOI due March 6, 2017

ALBERTA-WIDE Funding Opportunity

The Alberta Diabetes Institute at the University of Alberta is pleased to announce a collaboration with Janssen Pharmaceuticals and its parent company Johnson & Johnson to advance early-stage technologies related to Type I and Type II diabetes. The Alberta Diabetes Institute – Johnson & Johnson Diabetes Research Fund is a $600,000 partnership between Alberta Diabetes Foundation, Janssen Inc. (Johnson & Johnson) and the Government of Alberta.  The three year competitive fund, administered by U of A’s Alberta Diabetes Institute, will support research in either Type I or Type II diabetes with a focus on highly novel hypothesis-testing for targets, agents, therapies, diagnostics, etc., discovery research with a high potential for commercialization.

This is the third year of funding and this year’s Letter of Intent due Monday, March 6, 2017.  LOIs will be evaluated by a review committee that includes industry representation. This will be followed by invitation for full application. Up to a maximum of $50,000 for one year may be requested.

Visit http://adi.ualberta.ca/en/FundingOpportunities/ADIandJJResearchFund.aspx for more information.

Timelines

  • Letter of Intent due March 6, 2017
  • Notification of approval to submit full application March 20, 2017
  • Full application due April 17, 2017
  • Notification of funding May 23, 2017

Note:  You do not have to be a member of the ADI to apply for this funding

%d bloggers like this: